In CRC, NGS is routinely employed to detect therapeutically and prognostically relevant alterations in genes including KRAS, NRAS, BRAF, PIK3CA, TP53, and the mismatch-repair (MMR) genes [22]. This evidence concerns the gene TP53 and colorectal carcinoma.